Heterogeneous distribution of EGFR mutation in NSCLC: Case report
暂无分享,去创建一个
Z. Benbrahim | L. Bouguenouch | B. Alami | Y. Ouadnouni | M. Smahi | M. Serraj | B. Amara | N. Mellas | Fatima El Agy | H. El fatemi | S. Gamrani | S. Boukansa | Sanae El Bardai | Ismail Mouhrach | S. El Bardai | L. Bouguenouch
[1] J. Tost,et al. Pyrosequencing , 2020, Definitions.
[2] Jin-Ji Yang,et al. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level , 2019, BMC Cancer.
[3] M. Maemondo,et al. Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing. , 2019, Future oncology.
[4] Junling Li,et al. Clinicopathologic characteristics and outcome of patients with different EGFR mutations , 2018, Asia-Pacific journal of clinical oncology.
[5] Jialei Wang,et al. Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review , 2017, Targeted oncology.
[6] Lisa M Haley,et al. Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma , 2016, Oncotarget.
[7] Baorui Liu,et al. EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature. , 2016, Oncology letters.
[8] G. Botti,et al. Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma , 2015, PloS one.
[9] M. Fassan,et al. Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma , 2015, Oncotarget.
[10] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[11] Z. Szallasi,et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution , 2014, Science.
[12] P. Laurent-Puig,et al. Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis? , 2014, Journal of Translational Medicine.
[13] C. Capella,et al. Pyrosequencing for EGFR Mutation Detection: Diagnostic Accuracy and Clinical Implications , 2013, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[14] A. Warth,et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies , 2012, Virchows Archiv.
[15] J. Sørensen,et al. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer , 2012, Cancer Chemotherapy and Pharmacology.
[16] K. Matsuo,et al. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] S. Lantuejoul,et al. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC , 2011, Journal of experimental & clinical cancer research : CR.
[18] Kaoru Irisa,et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). , 2010, Japanese journal of clinical oncology.
[19] M. Saegusa,et al. EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance , 2008, International journal of cancer.
[20] Kikuya Kato,et al. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.
[21] M. Tsao,et al. Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[22] James R. Knight,et al. Genome sequencing in microfabricated high-density picolitre reactors , 2005, Nature.
[23] Xuan Pan,et al. Response to EGFR-TKI in patients with gastrointestinal metastasis from primary lung adenocarcinoma : report of two cases , 2016 .